La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Cytophage Technologies a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Cytophage Technologies..

Cytophage Technologies (OTC:CPTCF) Azioni, Catena delle Opzioni

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.

CYTOPHAGE TECHS INC by CYTOPHAGE TECHNOLOGIES INC

Cytophage Technologies Ltd

<h2 class="wp-block-heading">Coronado Global Resources: Uncovering a Diamond in the Rough</h2>
As the search for 2025's breakout stocks heats up, one name in the often-overlooked coal sector keeps rising to the surface: Coronado Global Resources (ASX: CRN). At first glance, coal might seem like an unlikely candidate in a world obsessed with clean energy. But <a href="https://coronadoglobal.com/">Coronado</a> isn't your average coal company. Specializing in metallurgical coal-the lifeblood of steel production-it operates in a niche that's far less vulnerable to the environmental pressures battering thermal coal. Trading at just 17 cents per share, down significantly from its post-IPO highs, Coronado feels like a stock that's been unfairly punished. Could this be the speculative gem that delivers outsized returns in 2025? Let's dive into its story and find out.
<h2 class="wp-block-heading">The Coronado Edge: A Metallurgical Marvel</h2>
Coronado Global Resources, headquartered in Australia, is a focused player in the metallurgical coal market. Its crown jewel lies in Queensland's Bowen Basin, a world-class coal region, with additional operations in the United States. Producing 15.3 million tons in the 2024 financial year, with expectations of growth in 2025 driven by new projects, the company supplies premium products like Hard Coking Coal (HCC), alongside Semi-Hard/Semi-Soft Coking Coal and Pulverized Coal Injection (PCI) Coal-all critical for steelmaking.
What sets Coronado apart is its singular focus on metallurgical coal, which enjoys a unique position in the industry. While thermal coal, used for power generation, faces growing regulatory headwinds, metallurgical coal remains indispensable. In 2025, thermal coal prices hover around $94.75 per ton, but metallurgical coal commands $190 per ton, a premium that underscores the resilience of Coronado's market. With clients like China, the USA, and Japan's Nippon Steel, the company benefits from steady demand across global steel hubs. But Coronado's appeal goes beyond production-it's a story of financial grit and untapped potential.
<h2 class="wp-block-heading">Financial Fortitude: A Balance Sheet Built to Last</h2>
In an industry where debt can be a death knell, Coronado stands out for its financial discipline. For the full 2024 financial year, the company reported $2.51 billion in revenue, though it swung to a net loss of $108.9 million, down from a profit of $156.1 million the prior year. Its net debt stood at $85 million, a manageable figure given its operational scale.
While the net loss reflects challenges like falling coal prices and operational hurdles, Coronado's relatively low debt is a rarity in the coal sector, where high leverage often amplifies risks. This lean balance sheet gives it room to maneuver-whether that means funding growth projects or weathering price dips without breaking a sweat. It's the kind of stability that makes investors take notice, especially when the stock price tells a very different story.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="612" height="458" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20121625/istockphoto-2190365233-612x612-1.jpg" alt="" class="wp-image-13152" style="width:558px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20121625/istockphoto-2190365233-612x612-1.jpg 612w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20121625/istockphoto-2190365233-612x612-1-300x225.jpg 300w" sizes="(max-width: 612px) 100vw, 612px" /></figure>
<h2 class="wp-block-heading">From IPO Glory to Rock Bottom: What Happened?</h2>
When Coronado went public on the Australian Securities Exchange in 2018, raising $500 million, it was a coal industry darling. Shares soared to the $1.50-2.50 range, fueled by optimism about its metallurgical focus. But the years since have been brutal. The COVID-19 pandemic disrupted global markets, metallurgical coal prices softened in 2024, and a failed deal to sell a controlling stake to Swedish firm Seven shattered investor confidence. The result? A stock now trading at a mere 17 cents.
It's tempting to write Coronado off as a has-been, but that might be premature. Its production remains robust, its assets are top-tier, and the steep share price drop could reflect market overreaction rather than fundamental weakness. Some analysts predict a rebound to $1.50-2.50, suggesting a potential 9-15x return for patient investors. To understand the opportunity, though, we need to confront the challenges head-on.
<h2 class="wp-block-heading">Navigating 2024's Storms: A Tough Year in Review</h2>
Coronado didn't have an easy ride in 2024. It produced 15.3 million tons, but faced significant headwinds. Metallurgical coal prices weakened, with 2025 prices at around $190 per ton, down from peaks of $300 per ton in 2024. Fitch Ratings had forecast a further slide to $120 per ton by 2025, though current prices are holding above that level, signaling some market resilience. Higher taxes and royalties in Queensland added pressure, while technical issues at the Curragh complex drove up costs and crimped output. The collapsed "Seven" deal was the final blow, leaving investors wary.
From a technical perspective, the stock remains in a downtrend, signaling caution for would-be buyers. Jumping in now risks catching a falling knife. Yet, even in these dark clouds, there's a silver lining-Coronado is laying the groundwork for a brighter future.
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="636" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20124809/image-8-1024x636.png" alt="" class="wp-image-13155" style="width:614px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20124809/image-8-1024x636.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20124809/image-8-300x186.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20124809/image-8-768x477.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/20124809/image-8.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">A Turnaround in the Making: Growth on the Horizon</h2>
Coronado isn't sitting idle. In December 2024, the company launched its Mammoth underground mine, a project set to boost production efficiency. Meanwhile, the Buchanan mine expansion in the USA promises to scale up output, with projections of up to 2.5 million additional tons per year once fully ramped up. With 300 million tons of reserves in the Bowen Basin, Coronado has over two decades of premium coal to mine, ensuring long-term relevance in a steel-hungry world.
The company is also sharpening its edge through cost optimization and market diversification, reducing reliance on any single region. If coal prices stabilize and these initiatives deliver, Coronado could be on the cusp of a renaissance. But how does it stack up against the industry's heavyweights?
<h2 class="wp-block-heading">Coronado vs. the Titans: Small but Mighty</h2>
With 15.3 million tons of production in 2024, Coronado is a pretty small, compared to giants like China Energy Investment (600+ million tons) or Coal India Limited (700+ million tons). Even Glencore (100 million tons) and BHP Group (40 million tons) surpass it in scale. Yet, size isn't everything. Coronado's metallurgical focus gives it an edge over diversified players, many of whom are exposed to the declining thermal coal market. In a world where steel remains king, Coronado's niche could be its greatest asset.
<h2 class="wp-block-heading">The Bottom Line: A High-Stakes Bet Worth Considering</h2>
So, why pick Coronado Global Resources for 2025? It's a high-risk, high-reward play that hinges on a few key factors. Its solid finances, premium assets, and upcoming projects paint a picture of a company with staying power. If metallurgical coal prices stabilize and Coronado's growth plans bear fruit, a share price recovery to $1.50-2.50 could transform it into a standout performer, offering 9-15x gains.
But the risks are real. Coal price volatility, regulatory pressures, and operational hiccups could keep the stock under pressure. Technical indicators urge caution, suggesting investors wait for a trend reversal before diving in. For those with the stomach for risk, though, Coronado represents a rare opportunity-a undervalued player in an essential industry, ready to reclaim its shine back again.

Equities

Long Ideas

Commodities

Global

Opinion

Markets

Trading Ideas

A Coal Stock Poised For A 2025 Comeback?

Second Quarter and Full Year Fiscal 2026 Outlook
The Company's second quarter and full year Fiscal 2026 guidance below assumes that the current level of tariffs on imports into the U.S. from China and other countries as of May 21, 2025 will stay in place for the remainder of the year. The Company's full year Fiscal 2026 guidance assumes that it can offset the significant incremental pressure it has experienced and continues to expect from tariffs.
For the second quarter of Fiscal 2026, the Company expects consolidated comparable sales to be up 2% to 3%. The Company is planning second quarter Fiscal 2026 pretax profit margin to be in the range of 10.4% to 10.5%, down 0.4 to 0.5 percentage points versus the prior year's 10.9%. The Company is planning second quarter Fiscal 2026 diluted earnings per share to be in the range of $.97 to $1.00, which would represent a 1% to 4% increase versus the prior year's $.96. The Company's second quarter Fiscal 2026 outlook includes an incremental negative impact from tariff costs on the merchandise it was committed to at the time additional tariffs were announced in March and April of 2025.
For the full year Fiscal 2026, the Company continues to expect consolidated comparable sales to be up 2% to 3%. The Company continues to plan full year Fiscal 2026 pretax profit margin to be in the range of 11.3% to 11.4%, down 0.1 to 0.2 percentage points versus the prior year's 11.5%. The Company continues to expect full year Fiscal 2026 diluted earnings per share to be in the range of $4.34 to $4.43, which would represent a 2% to 4% increase over the prior year's $4.26. For the full year Fiscal 2026, the Company is maintaining its assumption that unfavorable foreign currency exchange rates and transactional foreign exchange would have an approximately 0.2 percentage point negative impact to pretax profit margin and an approximately 3% negative impact to earnings per share growth.

News

Guidance

TJX Companies Sees Q2 GAAP EPS $0.97-$1.00 vs $1.03 Est

Bernstein analyst Peter Weed maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Outperform and lowers the price target from $229 to $225.

Price Target

Analyst Ratings

PANW

Bernstein Maintains Outperform on Palo Alto Networks, Lowers Price Target to $225

Bread Financial Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>) ("Bread Financial" or the "Company") today announced it has commenced a cash tender offer (the "Tender Offer") to purchase up to $150.0 million (subject to increase, the "Tender Cap") aggregate principal amount of its 9.750% Senior Notes maturing March 2029 (the "Notes"). The Tender Offer is being made on the terms and subject to the conditions set forth in the Offer to Purchase, dated May 21, 2025 (as it may be amended or supplemented, the "Offer to Purchase").
The Tender Offer will expire at 5:00 p.m., New York City time, on June 20, 2025, unless extended or earlier terminated as described in the Offer to Purchase (such date and time, as they may be extended, the "Expiration Time"), with an early participation deadline of 5:00 p.m., New York City time, on June 4, 2025 (the "Early Participation Date"), unless extended or earlier terminated.
The total consideration payable for each $1,000 principal amount of Notes will be determined based on a modified "Dutch Auction" procedure. Holders of the Notes ("Holders") who validly tender (and do not validly withdraw) their Notes before 5:00 p.m., New York City time, on the Early Participation Date, and whose Notes are accepted for purchase by the Company, will be eligible to receive the "Total Consideration," which includes an "Early Participation Amount" of $50.00 for each $1,000 principal amount of the Notes validly tendered.&nbsp;
The Company may, but is not obligated to, following the Early Participation Date and prior to the Expiration Time, elect to accept the Notes validly tendered by Holders on or prior to the Early Participation Date, for settlement on such date or promptly thereafter (the "Early Payment Date"). If the Company elects to have an Early Payment Date, it is currently expected to be June 9, 2025, though it will issue a press release announcing the date selected as the Early Payment Date.&nbsp;
Holders who validly tender their Notes after the Early Participation Date and on or prior to the Expiration Time, and who have their Notes accepted for purchase by the Company, will not be eligible to receive the Early Participation Amount and will only receive the Total Consideration minus the Early Participation Amount (the "Tender Offer Consideration") on the final payment date (the "Final Payment Date"). The Final Payment Date is currently expected to occur on June 25, 2025.

Bread Financial Holdings Commences Cash Tender Offer To Purchase Up To $150M Aggregate Principal Amount Of 9.750% Senior Notes Maturing March 2029

Jefferies analyst David Chiaverini initiates coverage on BOK Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) with a Hold rating and announces Price Target of $105.

Initiation

BOKF

Jefferies Initiates Coverage On BOK Financial with Hold Rating, Announces Price Target of $105

Financing

Caliber Announced Today The Successful Closing Of A $22.5M Refinance For The Doubletree By Hilton Hotel In Tucson, Arizona

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.66) by 89.39 percent. This is a 82.05 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $3.96 million which missed the analyst consensus estimate of $5.20 million by 23.91 percent. This is a 20.33 percent decrease over sales of $4.96 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

MDWD

MediWound Q1 EPS $(0.07) Beats $(0.66) Estimate, Sales $3.96M Miss $5.20M Estimate

CIBC Asset Management Announced The Launch Of The New CIBC Income Advantage Fund And CIBC U.S. Dollar Income Advantage Fund

WIIM

QIPT

Quipt Home Medical Corp. shares are trading higher after the company confirmed the receipt of an unsolicited acquisition proposal from Forager Capital Management for $3.10 per share.

Comparable Sales by Division
The Company's comparable sales by division for the first quarter of Fiscal 2026 and Fiscal 2025 were as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">First Quarter&nbsp; Comparable Sales1</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">FY2026</td>
<td colspan="1" rowspan="1">FY2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Marmaxx (U.S.)2</td>
<td colspan="1" rowspan="1">+2%</td>
<td colspan="1" rowspan="1">+2%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">HomeGoods (U.S.)3</td>
<td colspan="1" rowspan="1">+4%</td>
<td colspan="1" rowspan="1">+4%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">TJX Canada</td>
<td colspan="1" rowspan="1">+5%</td>
<td colspan="1" rowspan="1">+4%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">TJX International (Europe &amp; Australia)4</td>
<td colspan="1" rowspan="1">+5%</td>
<td colspan="1" rowspan="1">+2%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">TJX</td>
<td colspan="1" rowspan="1">+3%</td>
<td colspan="1" rowspan="1">+3%</td>
</tr>
</tbody>
</table>
</figure>

TJX Companies Q1 Comparable Sales +3%, Marmaxx +2%, HomeGoods +4%, TJX Canada +5%, TJX International (Europe & Australia) +5%

Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QIPT#NASDAQ">QIPT</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/QIPT#TSX">QIPT</a>), a U.S. based home medical equipment provider focused on end-to-end respiratory care, today announced that it has received an unsolicited non-binding and conditional and indicative proposal from Forager Capital Management, LLC ("FCM") to acquire 100% of the Company's issued and outstanding common shares at a price of $3.10 per common share (the "Non-Binding Proposal").
It is the Company's policy not to comment on unsolicited offers and is confirming its receipt of the Non-Binding Proposal only because Forager has made it public. As previously disclosed, the Company entered into a Non-Disclosure and Standstill Agreement (the "Agreement"), dated February 1, 2025, with Forager Fund, L.P. ("Forager Fund") and FCM (collectively, with Forager Fund, "Forager"). The Agreement provides that Forager, and other representatives of Forager will, for a period of six (6) months after the date of the Agreement, not directly or indirectly acquire (or propose or agree to acquire), by purchase or otherwise, any equity securities or assets of Quipt, or rights or options to acquire interests in any of Quipt's equity securities or assets (the "Standstill") without the prior advance approval in writing by the Board of Directors of the Company (the "Board"). The Agreement also provides for customary terms related to the non-disclosure and use of confidential information of Quipt. The Board did not provide Forager with any prior written approval for a waiver of the confidentiality provision or the Standstill provision relating to the issuance of the Non-Binding Proposal.
In consultation with its financial and legal advisors, the Board remains focused on the best long-term interests of the Company to drive sustainable value for its shareholders. The Company does not intend to comment further on the Non-Binding Proposal, unless it is required to do so in accordance with applicable law.

TSX:QIPT

Quipt Home Medical Receives Unsolicited Non-Binding, Conditional And Indicative Acquisition Proposal From Forager Capital Management At $3.10/Shr

The Trump administration has put a halt to a lawsuit against&nbsp;Southwest Airlines&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) that was initiated by the Biden administration over alleged persistent flight delays.
What Happened: A Southwest spokesperson <a href="https://www.foxbusiness.com/economy/trump-admin-drops-biden-era-southwest-airlines-lawsuit-over-delays?ref=biztoc.com">told </a>Fox Business that the company appreciated the Department of Transportation's decision to drop its lawsuit, adding that they believed it was the correct outcome in this case.
The lawsuit, filed during the final days of the Biden administration, accused Southwest Airlines of &#8220;illegally operating multiple chronically delayed flights and disrupting passengers' travel.&#8221; The two flights at the heart of the lawsuit were between Chicago Midway International Airport and Oakland, California and Baltimore and Cleveland.
The lawsuit claimed that the flights experienced chronic delays for five consecutive months, affecting 180 passengers between April and August 2022. The Biden administration also accused Southwest Airlines of &#8220;unfair, deceptive and anticompetitive&#8221; conduct by allegedly providing inaccurate departure and arrival times.
However, a spokesperson for Southwest Airlines told Fox Business that the flights in question took place during the COVID-19 pandemic, a period of unparalleled challenges for the industry. 
The Department of Transportation (DOT) now maintains that the lawsuit should never have been filed. &#8220;Southwest has remedied the underlying issues and USDOT will work with them fairly, not sue them for political gain,&#8221; according to a DOT spokesperson.
SEE ALSO: <a href="https://benzinga.com/markets/cryptocurrency/25/05/45510057/senate-crypto-bill-passes-key-vote-genius-act-moves-toward-final-passage" target="_blank" rel="noreferrer noopener">Senate Crypto Bill Passes Key Vote, GENIUS Act Moves Toward Final Passage &#8211; Benzinga</a>
Why It Matters: The lawsuit against Southwest Airlines came at a time when airlines were facing a challenging start to 2025, with concerns centered around consumer behavior, domestic capacity and the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44087114/airlines-face-a-rough-start-to-2025-full-service-carriers-hold-the-advantage-analyst">effects of reduced</a> government travel. 
Southwest Airlines had also reported a volatile first quarter, with an <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44990066/whats-going-on-with-southwest-airlines-stock-thursday">adjusted loss</a> of 13 cents per share, beating analysts' estimate of a loss of 18 cents per share. The lawsuit&#8217;s dismissal could provide some relief to the airline, which has been working to improve its operational reliability.
Benzinga's Edge Rankings place Southwest Airlines in the 74th percentile for momentum and the 67th percentile for value, reflecting its strong performance in both areas. Check the detailed report <a href="https://www.benzinga.com/quote/LUV">here</a>. 
Over the past one month, the shares of Southwest Airlines surged 35.19%.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/general/travel/25/05/45516390/top-us-airports-see-sharpest-drop-in-arrivals-as-business-government-and-tourist-travel-decline" target="_blank" rel="noreferrer noopener">Top US Airports See Sharpest Drop In Arrivals As Business, Government And Tourist Travel Decline</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Trump Administration Halts Biden-Era Lawsuit Against Southwest Airlines Over Alleged Flight Delays

NLSP

NLS Pharmaceutics Announces That It Will Present New Preclinical Data On Mazindol Er At The 2025 Annual Meeting Of The American Society Of Clinical Psychopharmacology

Billionaire Elon Musk has shared a major Neuralink update at the Qatar Economic Forum with the Neurotechnology company's Brain-Chip Interface Blindsight set for its maiden trial next year.
What Happened: Speaking at the Qatar Economic Forum, the billionaire shared that Neuralink's Blindsight implant, which Musk says can help completely blind people see, will undergo its first clinical trial in 2026, he said on Tuesday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">NEWS: Elon Musk&#39;s company, Neuralink, has now successfully implanted its brain chip into five humans. The patients can control a mouse using only their thoughts. Neuralink aims to implant its new brain chip, Blindsight, into a human patient for the first time in late 2025/early… <a href="https://t.co/OJuX6robyT">pic.twitter.com/OJuX6robyT</a>
&mdash; Sawyer Merritt (@SawyerMerritt) <a href="https://twitter.com/SawyerMerritt/status/1924874992086310922?ref_src=twsrc%5Etfw">May 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
"We've got Neuralink, which has now helped five patients restore capability using the telepathy implants," Musk said and outlined how the patients can control computers with their thoughts through the BCI chip.
Musk then talked about Neuralink's Blindsight implants and that the company will be deploying its implant on the first patient to "restore sight with our Blindsight implant, which is at the end of this year or early next year," Musk said. The company will partner with the UAE's Cleveland Clinic for the trial, according to Musk.
Why It Matters: The news comes in as Musk<a href="https://www.benzinga.com/general/biotech/25/04/44892867/elon-musk-says-neuralink-will-help-blind-people-see-again-will-exceed-the-best-human-eyes"> had previously touted</a> Neuralink's capabilities through a post on X. "With Neuralink interfacing directly to the visual cortex, even those who are completely blind will be able to see again," Musk said in the post.
A man battling ALS also became Neuralink's <a href="https://www.benzinga.com/25/04/45032464/man-suffering-from-als-becomes-the-first-ever-non-verbal-recipient-elon-musks-neuralink-brain-implant">first non-verbal recipient </a>of a brain implant, as well as becoming the third recipient of the company's Brain-Chip Interface last month.
Neuralink was <a href="https://www.benzinga.com/general/biotech/25/04/44972585/elon-musks-neuralink-eyes-8-5-billion-pre-money-valuation-in-latest-funding-round-report">eyeing an $8.5 billion </a>pre-money valuation for its latest funding round, as the company aimed to raise over $500 million. Before this, Neuralink was valued at $3.5 billion following its funding round.
Elsewhere, Neuralink's competitor in the BCI sector, Precision Neuroscience, had successfully <a href="https://www.benzinga.com/24/12/42523165/elon-musks-neuralink-faces-fierce-competition-as-precision-neuroscience-raises-102-million-to-advance-thought-controlled-devices">raised $104 million</a> in the company's funding round late last year.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/03/44358022/paralyzed-man-moves-objects-with-his-mind-thanks-to-elon-musks-brain-chip">Paralyzed Man Moves Objects With His Mind—Thanks To Elon Musk&#8217;s Brain Chip</a></li>
</ul>
Photo courtesy: rafapress / Shutterstock.com

Biotech

Tech

Elon Musk Says Neuralink Has Implanted Brain Chips In 5 Humans—Next Up: Restoring Vision With 'Blindsight' By 2026

TJX Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.90 by 2.22 percent. This is a 1.08 percent decrease over earnings of $0.93 per share from the same period last year. The company reported quarterly sales of $13.11 billion which beat the analyst consensus estimate of $13.00 billion by 0.83 percent. This is a 5.06 percent increase over sales of $12.48 billion the same period last year.

TJX Companies Q1 EPS $0.92 Beats $0.90 Estimate, Sales $13.11B Beat $13.00B Estimate

Jefferies analyst David Chiaverini initiates coverage on Banc of California (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BANC#NYSE">BANC</a>) with a Buy rating and announces Price Target of $18.

BANC

Jefferies Initiates Coverage On Banc of California with Buy Rating, Announces Price Target of $18

SaaS website builder platform&nbsp;Wix.com Ltd&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>)&nbsp;reported its&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45534891/wix-reports-first-quarter-2025-results" rel="noreferrer noopener">fiscal first-quarter</a> 2025 results on Wednesday.&nbsp;The quarterly revenue grew 13%&nbsp;year-over-year&nbsp;to $473.7 million, topping the&nbsp;analyst consensus estimate of $472.9 million.&nbsp;Adjusted EPS of $1.55 missed the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate</a> of $1.60.
Creative Subscription revenue increased 11%&nbsp;Y/Y&nbsp;to $337.7 million.&nbsp;Creative Subscriptions bookings&nbsp;climbed 10%&nbsp;Y/Y&nbsp;to $369.5 million.&nbsp;Creative Subscriptions Annualized Recurring Revenue (ARR) was $1.37 billion, up 10%&nbsp;Y/Y.
Partners revenue&nbsp;in the&nbsp;quarter&nbsp;was&nbsp;$171.6 million, up&nbsp;24%&nbsp;Y/Y. Business&nbsp;Solutions&#8217;&nbsp;revenue rose 18%&nbsp;Y/Y&nbsp;to $136.0 million, and bookings jumped 15%&nbsp;Y/Y&nbsp;to $141.4 million.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45527790/goldman-sachs-bets-on-jpmorgan-praises-market-share-gains-efficiency" rel="noreferrer noopener">Goldman Sachs Bets On JPMorgan, Praises Market Share Gains, Efficiency</a>
The adjusted gross margin grew by 100 bps to 69%. During the quarter, Wix.com generated $145.5 million in operating cash flow and held $1.07 billion in cash and equivalents.
Wix&#8217;s Board authorized an increase to its stock buyback program to repurchase the company&#8217;s securities by up to $200 million, bringing the total repurchase authorization under the program to up to $400 million.
Wix.com <a href="https://www.benzinga.com/25/02/43812289/wix-q4-earnings-beats-estimates-raises-2025-outlook-ai-powered-expansion-and-market-share-gains" target="_blank" rel="noreferrer noopener">reiterated fiscal 2025</a> revenue outlook of $1.97 billion to $2 billion versus the analyst consensus estimate of $2.02 billion and bookings of  $2.03 billion to $2.06 billion. This company said this outlook reflects conservatism due to macro uncertainty, specifically the Business Solutions segment, with potential volatility offset by fully dissipating foreign exchange headwinds.
The company reiterated free cash flow outlook, excluding headquarters costs, of $590 million to $610 million. Wix.com expects second-quarter fiscal 2025 revenue of $485 million to $489 million versus the <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">analyst consensus estimate</a> of $490.53 million.
Lior Shemesh, CFO at Wix, said, &#8220;Our strong first quarter results demonstrate the critical value of the Wix platform to anyone and everyone requiring an online presence globally amid an ever-evolving macro environment, particularly SMBs. Top of funnel demand was very strong with Q1&#8217;25 new user cohort bookings finishing 12% higher than the bookings generated by the Q1&#8217;24 cohort in its first quarter.&#8221;
Price Action: WIX stock is trading lower by 1.78% to $178.50 premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/02/43861604/wixs-new-ai-products-and-studio-adoption-spark-bullish-analyst-calls-despite-fx-headwinds" target="_blank" rel="noreferrer noopener">Wix Is One Of The Best Product-Driven Growth Stories, Analyst Says</a></li>
</ul>
Image by Teo K via Shutterstock

Buybacks

Movers

Wix.com Issues Conservative Outlook Due To Macro Uncertainty, Increases Stock Buyback

HSBC analyst Sidharth Sahoo downgrades UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) from Hold to Reduce and lowers the price target from $490 to $270.

Downgrades

HSBC Downgrades UnitedHealth Group to Reduce, Lowers Price Target to $270

Jefferies analyst David Chiaverini initiates coverage on Atlantic Union Bankshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AUB#NYSE">AUB</a>) with a Buy rating and announces Price Target of $37.

Jefferies Initiates Coverage On Atlantic Union Bankshares with Buy Rating, Announces Price Target of $37

HSBC upgrades Bilibili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) from Hold to Buy and raises the price target from $21.5 to $22.5.

Comments

Cytophage Technologies

Cytophage Technologies (CPTCF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO